Efanesoctocog alfa

Efanesoctocog alfa is a recombinant DNA derived, coagulation factor VIII (FVIII) product, indicated for use in the control and prevention of bleeding episodes in patients with hemophilia A. It is a long-acting, human FVIII molecule with a single glycopeptide that extends its half-life in circulation.

Mechanism of Action

Efanesoctocog alfa works by replacing the missing coagulation FVIII that hemophilia A patients need for effective hemostasis. The FVIII is activated by thrombin and functions as a cofactor for factor IXa which, in the presence of calcium and phospholipids, converts factor X to the activated form (Xa). The factor Xa then converts prothrombin into thrombin, which leads to fibrin clot formation.

Pharmacokinetics

Efanesoctocog alfa is administered intravenously. The pharmacokinetics of efanesoctocog alfa are similar to those of other FVIII products. The half-life of efanesoctocog alfa is extended due to the single glycopeptide, allowing for less frequent dosing.

Adverse Effects

The most common adverse effects of efanesoctocog alfa include headache, rash, and fever. Serious adverse effects may include development of FVIII inhibitors, which can lead to a loss of clinical response. In such cases, alternative therapies may be required.

Contraindications

Efanesoctocog alfa is contraindicated in patients who have had life-threatening hypersensitivity reactions to the product or its components.

Drug Interactions

No specific drug interactions have been identified with efanesoctocog alfa. However, it should be used with caution in patients receiving concomitant anticoagulants.

References

‎